Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT04894994
Title FLX475 in Combination With Ipilimumab in Advanced Melanoma
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements No
Sponsors RAPT Therapeutics, Inc.
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.